Top Page
Opyl Ltd.
(Sydney:PKY)
Opyl Ltd. (PKY) vs. iShares MSCI Australia ETF (EWA)
Opyl Ltd. Business Overview & Revenue Model
Opyl Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.42K | 27.78K | 397.64K | 397.64K | 617.91K | 902.41K |
| Gross Profit | 0.00 | -778.89K | -1.40M | -1.86M | -930.36K | -809.62K |
| EBITDA | -871.84K | -1.66M | -2.68M | -1.70M | -2.27M | -1.14M |
| Net Income | -677.18K | -1.45M | -3.13M | -3.13M | -1.73M | -2.09M |
Balance Sheet | ||||||
| Total Assets | 881.60K | 513.28K | 411.60K | 411.60K | 709.58K | 979.22K |
| Cash, Cash Equivalents and Short-Term Investments | 580.84K | 436.90K | 374.64K | 452.88K | 786.33K | 2.32M |
| Total Debt | 0.00 | 411.73K | 0.00 | 300.00K | 300.00K | 0.00 |
| Total Liabilities | 356.22K | 781.65K | 501.76K | 501.76K | 712.21K | 314.75K |
| Stockholders Equity | 525.39K | -268.37K | -90.16K | -403.59K | 267.01K | 2.19M |
Cash Flow | ||||||
| Free Cash Flow | -455.54K | -1.29M | -2.07M | -1.37M | -1.53M | -918.13K |
| Operating Cash Flow | -455.54K | -1.28M | -2.06M | -1.36M | -1.52M | -903.65K |
| Investing Cash Flow | 0.00 | -334.02K | -17.71K | -2.22K | -2.22K | -14.48K |
| Financing Cash Flow | 664.41K | 1.35M | 2.00M | 1.03M | 1.03M | 2.43M |
Opyl Ltd. Technical Analysis
Opyl Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$15.18M | -1.71 | ― | ― | -67.78% | 37.78% | |
44 Neutral | AU$12.44M | -2.48 | ― | ― | 241.34% | 44.19% | |
43 Neutral | AU$80.50M | -6.64 | ― | ― | ― | ― | |
42 Neutral | AU$4.17M | -1.98 | ― | ― | -9.90% | 34.07% | |
40 Underperform | AU$10.09M | -0.96 | ― | ― | -40.05% | -49.57% |
Opyl Ltd. Corporate Events
Pathkey.ai Ltd has granted director Shannon Robinson 4 million unlisted options with an exercise price of A$0.03 and an expiry date of 20 August 2029, issued indirectly through Berger Investment Fund Pty Ltd. The options, which were granted for nil cash consideration as part of Robinson’s remuneration under the company’s incentive plan, increase her indirect interest in the company and further align her compensation with future share price performance, signalling continued use of equity-based incentives at the board level.
The award of long-dated, out-of-the-money options links Robinson’s potential upside closely to Pathkey.ai’s longer-term market valuation. This structure may be viewed positively by shareholders who favour performance-aligned governance, while also subtly indicating the board’s confidence in the company’s ability to create value over the coming years despite no immediate cash outlay by the director.
Pathkey.ai Ltd has notified the market of the issue of new unquoted equity securities under its employee incentive scheme. The company’s filing confirms its status as an ASX-listed entity with the issuer code PKY, but provides no further operational or industry details.
The company will issue 4,000,000 unquoted options, exercisable at $0.03 and expiring on 20 August 2029, with an issue date of 9 February 2026. These options are not intended to be quoted on the ASX, indicating a focus on internal incentives rather than immediate capital raising or secondary market trading.
Pathify.ai Ltd has disclosed a change in director Paul Niardone’s interests, with the director’s relevant interest held indirectly through Trindis Pty Ltd. While the notice does not detail the company’s operations, it confirms Niardone’s ongoing stake via both fully paid ordinary shares and unlisted options, clarifying his financial alignment with shareholders. The filing reports that on 4 February 2026 Niardone, via Trindis Pty Ltd, acquired 2,000,000 fully paid ordinary shares in a recent share placement at $0.012 per share, for total consideration of $24,000, and now holds 2,000,000 shares plus 2,000,000 unlisted options exercisable at $0.03 expiring on 20 August 2029. The transaction underscores continued director participation in capital raisings, which may be read by investors as a signal of confidence in the company’s prospects and governance alignment, although it does not alter any contractual interests.
The company lodged a cleansing notice confirming the issuance of 252,473,552 fully paid ordinary shares, stating that the shares were issued without a prospectus and that the company remains compliant with its financial reporting and continuous disclosure obligations under the Corporations Act, with no excluded information withheld from investors. This action signals PathKey.AI’s adherence to regulatory requirements while expanding its share base, providing transparency to stakeholders about dilution and positioning the firm for future capital or operational initiatives.
Pathkey.AI Ltd has applied to the Australian Securities Exchange for quotation of 10,195,580 new fully paid ordinary shares under its ASX code PKY. The application, lodged as an Appendix 2A on 4 February 2026 and linked to a shareholder resolution passed at a recent general meeting, will expand the company’s quoted share capital, potentially broadening its investor base and providing additional liquidity in the stock once the new securities commence trading.
PathKey.AI Ltd has notified the market of the issue of 175.5 million unquoted options in three new unlisted security classes, each with different exercise prices and maturities. The options, which are not intended to be quoted on the ASX, are exercisable at $0.025, $0.03 and $0.035 with two-, three- and four-year expiry terms respectively, representing a significant potential source of future equity for the company and possible dilution for existing shareholders if exercised.
PathKey.AI Ltd has lodged an Appendix 2A with the ASX seeking quotation of 48,728,425 ordinary fully paid shares under the code PKY, formalising their admission to trading on the exchange. The move significantly expands the number of quoted securities on issue and marks a key step in the company’s capital markets presence, potentially improving liquidity and visibility among investors as it builds its position in the Australian technology and AI sector.
Pathkey.ai operates in the artificial intelligence and data analytics sector, delivering AI-driven solutions that support enterprise decision-making and workflow automation across its target markets. The company has applied to list 5 million new fully paid ordinary shares on the ASX, completing a previously flagged issuance that expands its tradable float and signals ongoing capital formation to support growth initiatives.
Opyl Ltd (PATHKEY.AI Ltd, ASX: PKY) has lodged an updated Appendix 3B with the ASX outlining changes to a previously proposed issue of securities via a placement or similar capital-raising mechanism. The update revises the number and terms of options to be issued, aligning them with resolutions 3 and 4 from the company’s notice of meeting released on 29 December 2025, and supersedes details contained in its 27 November 2025 announcement, signalling adjustments to the structure of its planned equity incentives or capital management arrangements.
Opyl Ltd has updated its planned capital raise, scaling the issuance from 6.47 million to 5 million shares to Sandton Capital Advisory under Resolution 5, signaling a more targeted financing round aligned with its December 2025 shareholder approval. The smaller placement suggests a measured approach to balance-sheet support that may temper dilution while maintaining funding momentum for its AI-driven clinical research services.
Pathkey.ai operates in the AI technology sector, developing advanced data-driven solutions tailored for enterprise applications across the Australian market. The company has lodged an Appendix 2A to list 188,549,547 fully paid ordinary shares on the ASX, signaling the formal quotation of previously announced securities, which helps finalize its capitalization structure and supports liquidity for investors.
Pathkey.ai Ltd has announced the cessation of 1,780,000 unexercised options, designated as PKYAA, which expired on 10 December 2025 at various prices and dates. The expiry reduces the pool of potential dilutive securities on issue, slightly simplifying the company’s capital structure and signaling that these convertible instruments did not convert into ordinary equity before their deadline.
In its December 2025 quarter update, Pathkey outlined a period of consolidation marked by a strategic review that refines its positioning as an applied AI company beyond healthcare while keeping TrialKey as its lead commercial platform. The company strengthened governance with the appointments of Shannon Robinson as Non-Executive Chair and Paul Niardone as Non-Executive Director, advanced TrialKey’s large language model capabilities for ingesting and structuring large-scale clinical trial data, and initiated a collaboration with Armstrong Clinical to embed TrialKey analytics into early-phase clinical development workflows. Pathkey also moved to bolster its balance sheet with a $3.5 million capital raise to support growth, TrialKey commercialisation into new and existing verticals, and exploration of complementary AI opportunities, while implementing cost-reduction initiatives to better align spending with its current commercialisation stage without undermining execution capacity.
PathKey.AI Ltd has secured strong shareholder backing for a series of capital-raising and incentive-related measures at its latest general meeting. The company gained approval for the ratification and issuance of placement shares in two tranches, the grant of advisor and director options, and the issue of shares to key corporate advisors and communications providers, with all resolutions passing comfortably by poll, underscoring investor support for its current funding strategy and governance arrangements.
Pathkey.AI Ltd has applied to the ASX for quotation of 27,981,343 new ordinary fully paid shares, with an issue date of 12 January 2026, under its issuer code PKY. The move will expand the company’s quoted share capital, potentially enhancing liquidity in its stock and providing additional financial flexibility to support its future corporate and operational initiatives.
PathKey.AI Ltd has completed a pro-rata non-renounceable entitlement offer aimed at raising up to approximately A$920,517 through the issue of up to 76.7 million new shares at A$0.012 per share, on the basis of one new share for every four held. The offer resulted in shareholders taking up roughly 28.0 million shares for gross proceeds of about A$335,776, with a shortfall of approximately 48.7 million shares representing A$584,741 to be placed by the directors within three months, and the newly issued shares are set to begin trading on the ASX on 8 January 2026 on equal terms with existing stock, underpinning the company’s capital position and share liquidity.
Pathkey.AI Ltd has called a general meeting of shareholders to be held on 28 January 2026 at Allendale Square in Perth, Western Australia, with the formal notice outlining the time, location and purpose of the gathering. The document signals that shareholders will be asked to vote on a series of proposed resolutions detailed in accompanying materials, and encourages them to seek professional advice if unsure how to vote, underscoring the potential significance of the decisions for the company’s governance and strategic direction.
Pathkey.AI Ltd has announced a proposed issue of 188,549,547 ordinary fully paid securities, scheduled for January 23, 2026. This move is intended to raise capital through a placement or other type of issue, potentially impacting the company’s market positioning and offering new opportunities for stakeholders.
Pathkey.AI Ltd has announced the dispatch of offer documents for a non-renounceable pro-rata rights issue, allowing eligible shareholders to purchase one fully paid ordinary share for every four shares held. This offer, aimed at raising up to $920,517, follows a previous placement that raised $2,500,000 from sophisticated investors, and is part of the company’s broader capital raising efforts.
PathKey.AI Ltd has announced the issuance of 19,783,786 fully paid ordinary shares without disclosure to investors under the Corporations Act. The company confirms compliance with relevant provisions of the Corporations Act, and there is no excluded information as per the specified sections, indicating transparency and adherence to regulatory standards.
Pathkey.AI Ltd has announced a new application for the quotation of its securities on the Australian Securities Exchange (ASX). The company is set to quote 19,783,786 fully paid ordinary shares under the ASX code PKY, with the issue date being December 11, 2025. This move is part of a previously announced transaction, and it signifies a strategic step for Pathkey.AI in enhancing its market presence and potentially increasing its shareholder base.